The San Francisco Business Times (Free subscription) | 07/31/2009
Exelixis Inc. reported a second quarter loss of $44.8 million, or 42 cents a share, compared with a loss of $45.1 million, or 43 cents a share in the same period last year. (EXEL)
bizjournals (Free subscription) | 07/31/2009
Exelixis Inc. reported a second quarter loss of $44.8 million, or 42 cents a share, compared to a loss of $45.1 million, or 43 cents a share in the same period last year. (EXEL)
Volume Spike Investor (Free subscription) | 07/29/2009
Exelixis Inc. (Nasdaq: EXEL) shares are up more than 3 percent to $6.07 in premarket trading, on volume of about 34,000 shares as of 8:40 a.m. Eastern. There is no news out on the company, and no known new reports from analysts. Motley Fool mentioned the company rather passively in a story about biotechs being [...]
The East Bay Business Times (Free subscription) | 05/28/2009
Sanofi-Aventis will pay $140 million upfront to license two compounds from South San Francisco’s Exelixis Inc. as part of a broad cancer drug deal that could be worth as much as $1 billion. (EXEL) (SNY)
Financial24 (Free subscription) | 05/28/2009
Sanofi-Aventis SA bought rights to potential cancer drug candidates from Exelixis Inc. in a deal that may result in the French drugmaker paying more than $1 billion to its U.S. partner. The two companies will collaborate on research and Sanofi will 2 Vote(s)
Business Wire (Free subscription) | 03/13/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) announced today that George Scangos, PhD, the company’s president and chief executive officer, will present at the Cowen and Company 29th
The Earth Times Online Newspaper (Free subscription) | 03/06/2009
SOUTH SAN FRANCISCO, Calif. - Exelixis, Inc. (Nasdaq:EXEL) announced today that Michael Morrissey, PhD, the company’s President of Research & Development, will present at the Barclays Capital Global Healthcare Conference at 4:45 p.m. ET/1:45 p.m. PT on Tuesday, March 10, 2009. Dr.
Business Wire (Free subscription) | 03/06/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) announced today that Michael Morrissey, PhD, the company’s President of Research & Development, will present at the Barclays Capital
SeekingAlpha.com (Free subscription) | 03/05/2009
Exelixis, Inc. (EXEL) Q4 2008 Earnings Call Complete Story »
The East Bay Business Times (Free subscription) | 03/04/2009
Exelixis Inc. on Wednesday reported a fourth quarter loss of $38 million, or 36 cents a share, widened from a loss in the same period last year of $19.9 million, or 19 cents a share. (EXEL)
bizjournals (Free subscription) | 03/04/2009
Exelixis Inc. on Wednesday reported a fourth quarter loss of $38 million, or 36 cents a share, widened from a loss in the same period last year of $19.9 million, or 19 cents a share. (EXEL)
Business Wire (Free subscription) | 03/04/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2008.
Business Wire (Free subscription) | 02/25/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) will release its fourth quarter and full year 2008 financial results on Wednesday, March 4, 2009 after the markets close. The announcement will
Business Wire (Free subscription) | 02/05/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the company’s Executive Vice President and Chief Financial Officer, will present at the 11th Annual BIO
Nature (Free subscription) | 01/30/2009
Bristol–Myers Squibb (BMS) and Exelixis have entered into an agreement to co-develop two kinase inhibitors for oncology, including the multi-target kinase inhibitor XL184, which is currently in Phase III trials (Table 1).Under the terms of the collaboration, BMS agreed to pay Exelixis
Videos